Galectin Therapeutics reported $14.62M in Current Liabilities for its fiscal quarter ending in June of 2024.





Current Liabilities Change Date
AbbVie USD 43.1B 1.46B Sep/2026
Bristol-Myers Squibb USD 18.75B 94M Sep/2026
Galectin Therapeutics USD 14.62M 1.98M Jun/2024
Gilead Sciences USD 12B 982M Sep/2026
Immunic USD 31.55M 290K Sep/2026
Incyte USD 1.44B 125.72M Sep/2026
Merck USD 28.8B 1.07B Sep/2026